National Institute on Drug Abuse; Notice of Closed Meetings, 14572 [E9-6781]
Download as PDF
<![CDATA[
tjames on PRODPC61 with NOTICES
14572
Federal Register / Vol. 74, No. 60 / Tuesday, March 31, 2009 / Notices
Agenda: To review and evaluate grant
applications.
Place: Hilton—DC/Rockville, 1750
Rockville Pike, Rockville, MD 20852.
Contact Person: Michael B. Small, PhD,
Scientific Review Officer, Division of
Extramural Activities, National Cancer
Institute, National Institutes of Health, 6116
Executive Blvd., Room 8127, Bethesda, MD
20892–8328. 301–402–0996.
smallm@mail.nih.gov.
Name of Committee: National Cancer
Institute Special Emphasis Panel, NCI
Clinical Studies.
Date: June 15–17, 2009.
Time: 3 p.m. to 5 p.m.
Agenda: To review and evaluate grant
applications.
Place: Hilton Washington/Rockville, 1750
Rockville Pike, Rockville, MD 20852.
Contact Person: Majed M. Hamawy, PhD,
MBA, Scientific Review Officer, Research
Programs Review Branch, Division of
Extramual Activities, National Cancer
Institute, NIH, 6116 Executive Boulevard,
Room 8135, Bethesda, MD 20852. 301–594–
5659. mh101v@nih.gov.
Name of Committee: National Cancer
Institute Special Emphasis Panel, Cancer
Prevention, Control and Population Sciences.
Date: June 16–17, 2009.
Time: 8 a.m. to 6 p.m.
Agenda: To review and evaluate grant
applications.
Place: Hilton—Rockville, 1750 Rockville
Pike, Rockville, MD 20852.
Contact Person: Wlodek Lopaczynski, MD,
PhD, Scientific Review Officer, Research
Programs Review Branch, Division of
Extramural Activities, National Cancer
Institute, 6116 Executive Blvd., Room 8131,
Bethesda, MD 20892. 301–594–1402.
lopacw@mail.nih.gov.
Name of Committee: National Cancer
Institute Special Emphasis Panel, SPORE
Review.
Date: June 16–18, 2009.
Time: 4 p.m. to 5 p.m.
Agenda: To review and evaluate grant
applications.
Place: Bethesda North Marriott Hotel &
Conference Center, 5701 Marinelli Road,
Bethesda, MD 20852.
Contact Person: Shamala K. Srinivas, PhD,
Scientific Review Officer, Research Programs
Review Branch, Division of Extramural
Activities, National Cancer Institute, 6116
Executive Boulevard, Room 8123, Bethesda,
MD 20892, 301–594–1224, ss537t@nih.gov.
Name of Committee: National Cancer
Institute Special Emphasis Panel,
Application Use of Transformative Emerging
Technologies in Cancer Research.
Date: June 22–23, 2009.
Time: 8 a.m. to 6 p.m.
Agenda: To review and evaluate grant
applications.
Place: Bethesda Marriott, 5151 Pooks Hill
Road, Bethesda, MD 20814.
Contact Person: Viatcheslav A.
Soldatenkov, MD, PhD, Scientific Review
Officer, Special Review And Logistics
Branch, Division of Extramural Activities,
National Cancer Institute, 6116 Executive
Blvd., Room 8050a, Bethesda, MD 20892–
VerDate Nov<24>2008
14:35 Mar 30, 2009
Jkt 217001
8329, 301–451–4758,
soldatenkovv@mail.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.392, Cancer Construction;
93.393, Cancer Cause and Prevention
Research; 93.394, Cancer Detection and
Diagnosis Research; 93.395, Cancer
Treatment Research; 93.396, Cancer Biology
Research; 93.397, Cancer Centers Support;
93.398, Cancer Research Manpower; 93.399,
Cancer Control, National Institutes of Health,
HHS)
Dated: March 24, 2009.
Jennifer Spaeth,
Director, Office of Federal Advisory
Committee Policy.
[FR Doc. E9–7206 Filed 3–30–09; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute on Drug Abuse;
Notice of Closed Meetings
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. Appendix 2), notice
is hereby given of the following
meetings.
The meeting will he closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute on
Drug Abuse Special Emphasis Panel; Loan
Repayment.
Date: March 30, 2009.
Time: 9 a.m. to 5p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 6101
Executive Boulevard, Rockville, MD 20852
(Virtual Meeting).
Contact Person: Lyle Furr, Contract Review
Specialist, Office of Extramural Affairs,
National Institute on Drug Abuse, NIH,
DHHS, Room 220, MSC 8401, 6101 Executive
Boulevard, Bethesda, MD 20892–8401, (301)
435–1439, lf33c.nih.gov.
This notice is being published less than 15
days prior to the meeting due to the timing
limitations imposed by the review and
funding cycle.
Name of Committee: National Institute on
Drug Abuse Special Emphasis Panel; Mouse
Gene Development Initiative.
Date: May 6, 2009.
Time: 8 a.m. to 5 p.m.
PO 00000
Frm 00061
Fmt 4703
Sfmt 4703
Agenda: To review and evaluate grant
applications.
Place: Doubletree Hotel, 8120 Wisconsin
Avenue, Bethesda, MD 20814.
Contact Person: Minna Liang, PhD,
Scientific Review Officer, Training and
Special Projects Review Branch, Office of
Extramural Affairs, National Institute on
Drug Abuse, NIH, 6101 Executive Blvd.,
Room 220, MSC 8401, Bethesda, MD 20852,
301–435–1432, liangm@nida.nih.gov.
Name of Committee: National Institute on
Drug Abuse Special Emphasis Panel; Brain
Imaging Studies of Negative Reinforcement
in Humans.
Date: May 29, 2009.
Time: 8:30 a.m. to 6 p.m.
Agenda: To review and evaluate grant
applications.
Place: Embassy Suites at the Chevy Chase
Pavilion, 4300 Military Road, NW.,
Washington, DC 20015.
Contact Person: Kristen V Huntley, PhD,
Scientific Review Administrator, Office of
Extramural Affairs, National Institute on
Drug Abuse, NIH, DHHS, Room 220, MSC
8401, 6101 Executive Boulevard, Bethesda,
MD 20892–8401, 301–435–1433,
huntleyk@mail.nih.gov.
Name of Committee: National Institute on
Drug Abuse Initial Review Group; Health
Services Research Subcommittee.
Date: June 9–10, 2009,
Time: 8:30 a.m. to 6:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: Madison Lowes Hotel, 1177
Fifteenth Street, NW., Washington, DC
20005.
Contact Person: Meenaxi Hiremath, PhD,
Health Scientist Administrator, Office of
Extramural Affairs, National Institute on
Drug Abuse, National Institutes of Health,
DHHS, 6101 Executive Blvd., Suite 220, MSC
8401, Bethesda, MD 20892, 301–402–7964,
mh392g@nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.279, Drug Abuse and
Addiction Research Programs, National
Institutes of Health, HHS)
Dated: March 20, 2009.
Jennifer Spaeth,
Director, Office of Federal Advisory
Committee Policy.
[FR Doc. E9–6781 Filed 3–30–09; 8:45 am]
BILLING CODE 4140–01–M
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute on Drug Abuse;
Notice of Closed Meetings
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. Appendix 2), notice
is hereby given of the following
meetings.
The meeting will be closed to the
public in accordance with the
E:\FR\FM\31MRN1.SGM
31MRN1
]]>Agencies
[Federal Register Volume 74, Number 60 (Tuesday, March 31, 2009)]
[Notices]
[Page 14572]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E9-6781]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
National Institute on Drug Abuse; Notice of Closed Meetings
Pursuant to section 10(d) of the Federal Advisory Committee Act, as
amended (5 U.S.C. Appendix 2), notice is hereby given of the following
meetings.
The meeting will he closed to the public in accordance with the
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5
U.S.C., as amended. The grant applications and the discussions could
disclose confidential trade secrets or commercial property such as
patentable material, and personal information concerning individuals
associated with the grant applications, the disclosure of which would
constitute a clearly unwarranted invasion of personal privacy.
Name of Committee: National Institute on Drug Abuse Special
Emphasis Panel; Loan Repayment.
Date: March 30, 2009.
Time: 9 a.m. to 5p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, 6101 Executive Boulevard,
Rockville, MD 20852 (Virtual Meeting).
Contact Person: Lyle Furr, Contract Review Specialist, Office of
Extramural Affairs, National Institute on Drug Abuse, NIH, DHHS,
Room 220, MSC 8401, 6101 Executive Boulevard, Bethesda, MD 20892-
8401, (301) 435-1439, lf33c.nih.gov.
This notice is being published less than 15 days prior to the
meeting due to the timing limitations imposed by the review and
funding cycle.
Name of Committee: National Institute on Drug Abuse Special
Emphasis Panel; Mouse Gene Development Initiative.
Date: May 6, 2009.
Time: 8 a.m. to 5 p.m.
Agenda: To review and evaluate grant applications.
Place: Doubletree Hotel, 8120 Wisconsin Avenue, Bethesda, MD
20814.
Contact Person: Minna Liang, PhD, Scientific Review Officer,
Training and Special Projects Review Branch, Office of Extramural
Affairs, National Institute on Drug Abuse, NIH, 6101 Executive
Blvd., Room 220, MSC 8401, Bethesda, MD 20852, 301-435-1432,
liangm@nida.nih.gov.
Name of Committee: National Institute on Drug Abuse Special
Emphasis Panel; Brain Imaging Studies of Negative Reinforcement in
Humans.
Date: May 29, 2009.
Time: 8:30 a.m. to 6 p.m.
Agenda: To review and evaluate grant applications.
Place: Embassy Suites at the Chevy Chase Pavilion, 4300 Military
Road, NW., Washington, DC 20015.
Contact Person: Kristen V Huntley, PhD, Scientific Review
Administrator, Office of Extramural Affairs, National Institute on
Drug Abuse, NIH, DHHS, Room 220, MSC 8401, 6101 Executive Boulevard,
Bethesda, MD 20892-8401, 301-435-1433, huntleyk@mail.nih.gov.
Name of Committee: National Institute on Drug Abuse Initial
Review Group; Health Services Research Subcommittee.
Date: June 9-10, 2009,
Time: 8:30 a.m. to 6:00 p.m.
Agenda: To review and evaluate grant applications.
Place: Madison Lowes Hotel, 1177 Fifteenth Street, NW.,
Washington, DC 20005.
Contact Person: Meenaxi Hiremath, PhD, Health Scientist
Administrator, Office of Extramural Affairs, National Institute on
Drug Abuse, National Institutes of Health, DHHS, 6101 Executive
Blvd., Suite 220, MSC 8401, Bethesda, MD 20892, 301-402-7964,
mh392g@nih.gov.
(Catalogue of Federal Domestic Assistance Program Nos. 93.279, Drug
Abuse and Addiction Research Programs, National Institutes of
Health, HHS)
Dated: March 20, 2009.
Jennifer Spaeth,
Director, Office of Federal Advisory Committee Policy.
[FR Doc. E9-6781 Filed 3-30-09; 8:45 am]
BILLING CODE 4140-01-M
